PTGX
PROTAGONIST THERAPEUTICS INCData as of 2026 Q2 (06-30) · 13F snapshot
Summary
PROTAGONIST THERAPEUTICS INC (PTGX) is held as common stock by 3 tracked hedge-fund managers, with a combined reported value of ~$29.03M; the largest are Stanley Druckenmiller, Joel Greenblatt, Ray Dalio. 2 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 2 added, 1 trimmed, 1 closed. 2 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · LowThis quarter · Mixed
Common-stock holders32 also report options
Congress trades2
Price$142.44vs quarter-end+16.20%
Sectors0
This quarter's moves
Top holderNew0
Added2
Trimmed / sold2
Stanley DruckenmillerCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
Value $25.61M0.6% of portfolio208,9002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Stanley Druckenmiller | $25.61M | 0.6% | Add |
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $3.97M— of portfolio32,4002026 Q2
Value $1.64M— of portfolio13,4002026 Q2
Value $453.5K— of portfolio3,7002026 Q2
Value $257.4K— of portfolio2,1002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $3.97M | — | — |
| Ken GriffinPUT | $1.64M | — | — |
| Paul Tudor JonesCALL | $453.5K | — | — |
| Paul Tudor JonesPUT | $257.4K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.